Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Follicular lymphoma: BR in the frontline and pre-treatment PET

Paolo Strati • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Brentuximab vedotin Rituximab

Paolo Strati, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of BR vs. R-CHOP as an initial treatment for advanced follicular lymphoma (FL), and the prognostic value of a pre-treatment PET scan in FL patients receiving frontline therapy. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Paolo Strati

2:48
BTK inhibitors in the treatment of DLBCL: trials investigating these agents
Paolo Strati • 10 Dec 2023
2:14
Updates on the Smart Stop trial: the potential for a chemo-free regimen in the frontline for DLBCL
Paolo Strati • 10 Dec 2023
1:36
Loncastuximab tesirine as a consolidation strategy post-CAR T-cell therapy in DLBCL
Paolo Strati • 10 Dec 2023
1:55
Autologous SIRPα- low macrophages (SIRPant-M) enhance immune anti-tumor activity in R/R NHL
Paolo Strati • 10 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals